148 related articles for article (PubMed ID: 8685097)
1. [Cell proliferation in bone tumors. Immunohistologic study of Ki-67 protein expression].
Stenzel I; Pösl M; Ritzel H; Hentz M; Werner M; Delling G
Pathologe; 1996 Jan; 17(1):56-62. PubMed ID: 8685097
[TBL] [Abstract][Full Text] [Related]
2. [DNA cytometry of solitary and aneurysmal bone cysts and low malignancy and high malignancy central osteosarcomas. Current significance within the scope of morphologic diagnosis of intraosseous cystic and osteoblastic lesions].
Werner M; Heintz A; Delling G
Pathologe; 1996 Jan; 17(1):44-9. PubMed ID: 8685095
[TBL] [Abstract][Full Text] [Related]
3. Molecular analysis of p53, MDM2 and H-ras genes in low-grade central osteosarcoma.
Park HR; Jung WW; Bertoni F; Bacchini P; Park JH; Kim YW; Park YK
Pathol Res Pract; 2004; 200(6):439-45. PubMed ID: 15310147
[TBL] [Abstract][Full Text] [Related]
4. Expression of p53 protein, PCNA, and Ki-67 in osteosarcomas of bone.
Park HR; Park YK
J Korean Med Sci; 1995 Oct; 10(5):360-7. PubMed ID: 8750062
[TBL] [Abstract][Full Text] [Related]
5. MDM2 and CDK4 immunohistochemical coexpression in high-grade osteosarcoma: correlation with a dedifferentiated subtype.
Yoshida A; Ushiku T; Motoi T; Beppu Y; Fukayama M; Tsuda H; Shibata T
Am J Surg Pathol; 2012 Mar; 36(3):423-31. PubMed ID: 22301501
[TBL] [Abstract][Full Text] [Related]
6. [Pitfalls and typical false interpretations in bone tumors. From the viewpoint of long-term consultation].
Salzer-Kuntschik M
Pathologe; 1996 Jan; 17(1):1-5. PubMed ID: 8685089
[TBL] [Abstract][Full Text] [Related]
7. P63 expression as a biomarker discriminating giant cell tumor of bone from other giant cell-rich bone lesions.
Shooshtarizadeh T; Rahimi M; Movahedinia S
Pathol Res Pract; 2016 Oct; 212(10):876-879. PubMed ID: 27473669
[TBL] [Abstract][Full Text] [Related]
8. Low-grade intraosseous osteosarcoma in northern Japan: advantage of AgNOR and MIB-1 staining in differential diagnosis.
Okada K; Nishida J; Morita T; Kakizaki H; Ishikawa A; Hotta T
Hum Pathol; 2000 Jun; 31(6):633-9. PubMed ID: 10872654
[TBL] [Abstract][Full Text] [Related]
9. Clinical relevance of Ki-67 expression in bone tumors.
Scotlandi K; Serra M; Manara MC; Maurici D; Benini S; Nini G; Campanacci M; Baldini N
Cancer; 1995 Feb; 75(3):806-14. PubMed ID: 7828130
[TBL] [Abstract][Full Text] [Related]
10. [Osteosarcoma--apoptosis and proliferation. Study of bcl-2 expression].
Pösl M; Amling M; Werner M; Bäsler I; Salzer-Kuntschik M; Winkler K; Delling G
Pathologe; 1994 Dec; 15(6):337-44. PubMed ID: 7855102
[TBL] [Abstract][Full Text] [Related]
11. DNA cytometry of osteosarcoma.
Bauer HC
Acta Orthop Scand Suppl; 1988; 228():1-39. PubMed ID: 3063059
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical analysis of nm23 protein expression in malignant bone tumors.
Oda Y; Walter H; Radig K; Röse I; Neumann W; Roessner A
J Cancer Res Clin Oncol; 1995; 121(11):667-73. PubMed ID: 7593131
[TBL] [Abstract][Full Text] [Related]
13. Telomerase activity in benign bone tumors and tumor-like lesions.
Kido A; Schneider-Stock R; Hauptmann K; Roessner A
Pathol Res Pract; 1999; 195(11):753-7. PubMed ID: 10605695
[TBL] [Abstract][Full Text] [Related]
14. [Differential diagnosis of intramedullary osteosarcomas].
Hauptmann K; Melcher I; Schaser KD
Pathologe; 2008 Nov; 29 Suppl 2():240-4. PubMed ID: 18843492
[TBL] [Abstract][Full Text] [Related]
15. Primary versus radiation-associated craniofacial osteosarcoma: Biologic and clinicopathologic comparisons.
McHugh JB; Thomas DG; Herman JM; Ray ME; Baker LH; Adsay NV; Rabah R; Lucas DR
Cancer; 2006 Aug; 107(3):554-62. PubMed ID: 16795069
[TBL] [Abstract][Full Text] [Related]
16. Histological and immunohistochemical diversities, and proliferative activity and grading in osteosarcomas.
Hasegawa T; Hirose T; Seki K; Hizawa K; Ishii S; Wakabayashi J
Cancer Detect Prev; 1997; 21(3):280-7. PubMed ID: 9167046
[TBL] [Abstract][Full Text] [Related]
17. [Cytogenetic changes in low grade central osteosarcomas].
Werner M; Rieck J; Delling G
Verh Dtsch Ges Pathol; 1998; 82():189-94. PubMed ID: 10095432
[TBL] [Abstract][Full Text] [Related]
18. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody.
Thapar K; Kovacs K; Scheithauer BW; Stefaneanu L; Horvath E; Pernicone PJ; Murray D; Laws ER
Neurosurgery; 1996 Jan; 38(1):99-106; discussion 106-7. PubMed ID: 8747957
[TBL] [Abstract][Full Text] [Related]
19. The proliferation index of MIB-1 as a prognostic factor for patients with transitional cell carcinoma of the upper urinary tract.
Chowdhury GM; Kojima K; Kanayama H; Tsuji M; Kurokawa Y; Kagawa S
Cancer; 1996 Aug; 78(4):827-33. PubMed ID: 8756378
[TBL] [Abstract][Full Text] [Related]
20. p53 gene mutations in osteosarcomas of low-grade malignancy.
Radig K; Schneider-Stock R; Haeckel C; Neumann W; Roessner A
Hum Pathol; 1998 Nov; 29(11):1310-6. PubMed ID: 9824113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
